Crossref journal-article
Informa UK Limited
Future Medicinal Chemistry (301)
Bibliography

Renner, S., Popov, M., Schuffenhauer, A., Roth, H.-J., Breitenstein, W., Marzinzik, A., Lewis, I., Krastel, P., Nigsch, F., Jenkins, J., & Jacoby, E. (2011). Recent Trends and Observations in the Design of High-Quality Screening Collections. Future Medicinal Chemistry, 3(6), 751–766.

Authors 11
  1. Steffen Renner (first)
  2. Maxim Popov (additional)
  3. Ansgar Schuffenhauer (additional)
  4. Hans-Joerg Roth (additional)
  5. Werner Breitenstein (additional)
  6. Andreas Marzinzik (additional)
  7. Ian Lewis (additional)
  8. Philipp Krastel (additional)
  9. Florian Nigsch (additional)
  10. Jeremy Jenkins (additional)
  11. Edgar Jacoby (additional)
References 182 Referenced 56
  1. Bartlett PA EntzerothM. Exploiting Chemical Diversity for Drug Discovery. Royal Society of Chemistry Cambridge UK (2006). (10.1039/9781847552556)
  2. 10.1016/j.drudis.2006.02.001
  3. 10.2174/1568026053828376
  4. 10.1016/j.cbpa.2010.03.024
  5. 10.1002/(SICI)1097-0290(199824)61:1<61::AID-BIT11>3.0.CO;2-C
  6. 10.2174/092986709789712862
  7. 10.1016/j.bcp.2009.02.015
  8. 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6
  9. 10.1016/S1359-6446(97)01163-X
  10. 10.1002/anie.200462457
  11. 10.1021/ja902302h
  12. 10.1039/c0md00020e
  13. 10.1021/jm060217p
  14. 10.1021/jm801513z
  15. 10.1016/S0169-409X(00)00129-0
  16. Oprea TI , DavisAM, TeagueSJ, LeesonPD. Is there a difference between leads and drugs? A historical perspective.J. Chem. Inf. Model.41(5), 1308–1315 (2001). / J. Chem. Inf. Model. / Is there a difference between leads and drugs? A historical perspective. by Oprea TI (2001)
  17. 10.1021/jm000292e
  18. 10.1021/jm0492002
  19. 10.1038/nrd2445
  20. 10.1517/17460441003605098
  21. 10.1038/nchembio.180
  22. 10.1073/pnas.0404719101
  23. 10.1073/pnas.0503647102
  24. 10.1515/bc.2010.013
  25. 10.1038/nchembio.362
  26. 10.1038/nchem.730
  27. 10.1021/ci700286x
  28. 10.1021/ci050480j
  29. 10.1007/s11030-006-9054-0
  30. 10.1016/j.drudis.2008.10.011
  31. 10.1016/j.drudis.2009.07.014
  32. 10.1021/jm901241e
  33. 10.1021/jm1008456
  34. 10.1021/jm010934d
  35. 10.1016/j.cbpa.2010.03.020
  36. 10.1021/jm030266r
  37. 10.1021/jm030191r
  38. 10.1021/jm901137j
  39. 10.4155/fmc.10.237
  40. 10.1016/S1359-6446(04)03275-1
  41. 10.2174/138620708784911492
  42. 10.1021/ci0503558
  43. 10.1177/096032719101000405
  44. 10.1007/s10822-007-9105-3
  45. 10.1016/j.drudis.2010.08.004
  46. 10.2174/1568026054637700
  47. 10.1016/j.drudis.2007.08.005
  48. 10.1007/s10822-009-9280-5
  49. Hubbard RE , ChenI, DavisB. Informatics and modeling challenges in fragment-based drug discovery.Curr. Opin. Drug. Discov. Devel.10(3), 289–297 (2007). / Curr. Opin. Drug. Discov. Devel. / Informatics and modeling challenges in fragment-based drug discovery. by Hubbard RE (2007)
  50. 10.1016/j.sbi.2010.04.003
  51. 10.1038/nrd2220
  52. 10.1016/j.drudis.2009.04.007
  53. 10.1016/j.coph.2009.04.009
  54. 10.2174/156802607782341082
  55. 10.1158/0008-5472.CAN-07-5256
  56. 10.1038/nchembio.421
  57. 10.1073/pnas.89.12.5381
  58. 10.1016/j.cbpa.2010.02.017
  59. 10.1021/bc1001483
  60. 10.1126/science.287.5460.1964
  61. 10.1002/anie.200705415
  62. 10.1039/b816852k
  63. Galloway WR , Isidro-LlobetA, SpringDR. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules.Nat. Commun.1(6), (2010). / Nat. Commun. / Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. by Galloway WR (2010)
  64. 10.1021/jm9010687
  65. 10.1016/j.ccr.2006.08.027
  66. 10.1038/nrd2590
  67. 10.2174/156802610792232097
  68. 10.2174/092986709787002844
  69. 10.1021/ja900488a
  70. 10.1038/nrd1255
  71. 10.1210/jc.2009-2272
  72. 10.1210/jc.2008-1008
  73. 10.1088/0957-4484/21/6/065104
  74. 10.1166/jbn.2009.036
  75. 10.1038/nbt1228
  76. 10.1038/nrd2199
  77. Lackey KE . Gene family targeted molecular design. John Wiley & Sons Inc. Hoboken NJ USA (2008). (10.1002/9780470423936)
  78. 10.1016/S1074-5521(99)89004-8
  79. 10.1016/1047-8477(91)90048-2
  80. 10.1002/anie.200462643
  81. 10.1002/cmdc.200500008
  82. 10.1038/nchembio0709-436
  83. 10.1016/j.drudis.2009.10.010
  84. Sippl W JungM. Epigenetic Targets in Drug Discovery. Wiley-VCH Verlag GmbH & Co. KGaA Weinheim Germany (2009).
  85. 10.1021/ci025569t
  86. 10.1016/S0022-2836(02)00811-2
  87. 10.1016/j.jmb.2006.04.024
  88. 10.1093/nar/gkj062
  89. 10.1021/ci800289y
  90. 10.1021/ci1001263
  91. 10.1021/ci900349y
  92. 10.1002/cbic.200900604
  93. 10.1021/ci060003g
  94. 10.1021/jm060902w
  95. 10.1021/ci800023x
  96. 10.1371/journal.pcbi.1000397
  97. 10.1021/ci600300k
  98. 10.2174/138620708785739952
  99. 10.1021/ci6002043
  100. 10.1002/cmdc.200600147
  101. 10.1002/cbic.200400369
  102. 10.1002/cmdc.200700026
  103. 10.1021/ci800344p
  104. 10.1021/jm801546k
  105. 10.2174/138161209787315594
  106. 10.1021/jm00120a002
  107. 10.2174/1386207043328544
  108. 10.2174/138955707782331722
  109. 10.1016/j.cbpa.2010.02.018
  110. 10.1021/jm0502900
  111. 10.1021/ci8003896
  112. 10.1021/jm701021b
  113. 10.1093/bioinformatics/btn479
  114. 10.1021/ci600338x
  115. 10.1038/nchembio.188
  116. 10.1038/nchembio.187
  117. 10.1002/anie.200906555
  118. 10.1002/cmdc.200900419
  119. 10.1002/cmdc.201000272
  120. 10.1021/ci100203e
  121. 10.1007/s00018-009-0117-0
  122. 10.1126/science.273.5275.595
  123. 10.1093/bioinformatics/btg1086
  124. 10.1016/S0969-2126(97)00260-8
  125. 10.1093/nar/gkm993
  126. 10.1038/nbt1284
  127. 10.1038/nature08506
  128. 10.1126/science.1158140
  129. 10.1038/nrd3139
  130. Köppen H . Virtual screening – what does it give us?Curr. Opin. Drug Discovery Dev.12(3), 397–407 (2009). / Curr. Opin. Drug Discovery Dev. / Virtual screening – what does it give us? by Köppen H (2009)
  131. 10.1021/ja0771033
  132. 10.1006/jmbi.2001.4551
  133. 10.1021/jm8009958
  134. 10.1021/ci8003732
  135. 10.1007/s10822-010-9356-2
  136. 10.1111/j.1747-0285.2010.01041.x
  137. 10.1021/jp807701h
  138. 10.1021/jm030331x
  139. 10.1021/ci600342e
  140. 10.1021/ci900043r
  141. 10.1111/j.1747-0285.2009.00829.x
  142. 10.1023/A:1016399411208
  143. 10.1186/1758-2946-1-6
  144. 10.1007/s10822-009-9276-1
  145. 10.1016/j.drudis.2009.03.013
  146. 10.1021/ci100182c
  147. 10.1021/jm050114r
  148. 10.1021/ci700455u
  149. 10.1021/ci7004548
  150. 10.1021/ci8000265
  151. 10.1021/jm060167o
  152. 10.1021/ci7003626
  153. 10.1021/ci900199e
  154. 10.1007/s00894-008-0360-6
  155. 10.1002/qsar.200610091
  156. 10.2174/138955706778742768
  157. Mauser H , GubaW. Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discovery Dev.11(3), 365–374 (2008). / Curr. Opin. Drug Discovery Dev. / Recent developments in de novo design and scaffold hopping by Mauser H (2008)
  158. 10.1002/minf.201000019
  159. 10.1002/cmdc.200500005
  160. 10.1021/jm050468i
  161. 10.1021/jm100492z
  162. 10.1002/anie.200604125
  163. 10.1021/ci700418f
  164. 10.1007/BF00124349
  165. 10.1021/ci060094h
  166. 10.1021/jm061259g
  167. 10.1002/cmdc.200800355
  168. InFarmatik Kft www.infarmatik.com
  169. Prestwick Chemical www.prestwickchemical.com
  170. AnalytiCon Discovery GmbH www.ac-discovery.com
  171. Astex Therapeutics Ltd www.astex-therapeutics.com
  172. Evotec AG www.evotec.com
  173. Vernalis plc www.vernalis.com
  174. Ensemble Therapeutics www.ensemblediscovery.com
  175. Nuevolution A/S www.nuevolution.com
  176. Philochem AG www.philochem.ch
  177. GVK-BIO. GVK Bio database suite www.gvkbio.com
  178. EBI ChEMBL database www.ebi.ac.uk/chembl
  179. ExPASy Swiss-Prot www.expasy.ch/sprot
  180. NCBI OMIM database www.ncbi.nlm.nih.gov/omim
  181. EBI InterPro database www.ebi.ac.uk/interpro
  182. Breitenstein W Ehrhardt C Maibaum JK et al. Aminopiperidines and their preparation pharmaceutical compositions and use in the treatment of diseases associated with renin activity such as hypertension. PCT Int. Appl. (2007) 232 pp. CODEN: PIXXD2 WO 2007006534 A2 20070118 CAN 146:163026 AN 2007:61694 CAPLUS.
Dates
Type When
Created 14 years, 3 months ago (May 9, 2011, 2:51 p.m.)
Deposited 1 year, 3 months ago (May 23, 2024, 3:50 p.m.)
Indexed 1 year, 3 months ago (May 23, 2024, 4:40 p.m.)
Issued 14 years, 4 months ago (April 1, 2011)
Published 14 years, 4 months ago (April 1, 2011)
Published Online 14 years, 3 months ago (May 9, 2011)
Published Print 14 years, 4 months ago (April 1, 2011)
Funders 0

None

@article{Renner_2011, title={Recent Trends and Observations in the Design of High-Quality Screening Collections}, volume={3}, ISSN={1756-8927}, url={http://dx.doi.org/10.4155/fmc.11.15}, DOI={10.4155/fmc.11.15}, number={6}, journal={Future Medicinal Chemistry}, publisher={Informa UK Limited}, author={Renner, Steffen and Popov, Maxim and Schuffenhauer, Ansgar and Roth, Hans-Joerg and Breitenstein, Werner and Marzinzik, Andreas and Lewis, Ian and Krastel, Philipp and Nigsch, Florian and Jenkins, Jeremy and Jacoby, Edgar}, year={2011}, month=apr, pages={751–766} }